ForSight Vision5, which is developing devices to treat front-of-the-eye conditions such as glaucoma and dry eye disease, said today that it raised another $7.8 million.
ForSight Vision5 is a spinout of ForSight Labs, a Menlo Park, Calif.-based incubator focused on developing ophthalmic treatments. Last year the company reeled in a $15 million Series C round.
The company, which tapped medtech veteran John Maroney as CEO in 2013 after closing on a Series B1 round worth $9.3 million, is running a Phase II trial of its lead product candidate, the Helios ocular implant. The 160-patient trial is a randomized, active-controlled study of the Helios insert in patients with glaucoma and ocular hypertension.
Nine unnamed investors participated in the most recent offering, which consisted of debt, warrants and other securities, according to a regulatory filing.
